Back to top
more

Hikma Pharmaceuticals (HKMPF)

(Delayed Data from OTC)

$22.33 USD

22.33
NA

-1.92 (-7.92%)

Updated Apr 17, 2024 09:49 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for HKMPF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Hikma Pharmaceuticals Plc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 205 270 426 327 443
Receivables 873 841 876 792 798
Notes Receivable NA 0 0 0 0
Inventories 891 776 695 757 568
Other Current Assets 131 112 97 46 39
Total Current Assets 2,100 1,999 2,094 1,922 1,848
Net Property & Equipment 1,096 1,024 1,072 1,009 912
Investments & Advances 113 75 57 48 43
Other Non-Current Assets NA 0 0 0 0
Deferred Charges 226 192 183 221 243
Intangibles 1,100 1,124 892 876 834
Deposits & Other Assets NA 0 0 0 0
Total Assets 4,680 4,471 4,372 4,135 3,930
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable NA 0 0 0 0
Accounts Payable 568 476 468 470 473
Current Portion Long-Term Debt 150 139 112 158 569
Current Portion Capital Leases 11 9 9 10 9
Accrued Expenses NA 0 0 0 0
Income Taxes Payable 74 73 57 72 82
Other Current Liabilities 536 380 370 318 338
Total Current Liabilities 1,339 1,077 1,016 1,028 1,471
Mortgages NA 0 0 0 0
Deferred Taxes/Income 25 19 24 31 20
Convertible Debt NA 0 0 0 0
Long-Term Debt 975 1,074 651 692 48
Non-Current Capital Leases 55 61 74 72 59
Other Non-Current Liabilities 77 92 140 164 203
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 2,471 2,323 1,905 1,987 1,801
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) 40 40 42 41 41
Capital Surplus 282 282 282 282 282
Retained Earnings 2,158 2,092 2,189 1,892 1,973
Other Equity -271 -266 -46 -67 -167
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity 2,209 2,148 2,467 2,148 2,129
Total Liabilities & Shareholder's Equity 4,680 4,471 4,372 4,135 3,930
Total Common Equity 102,208 2,148 2,467 2,148 2,129
Shares Outstanding 220.20 220.20 242.30 242.30 242.30
Book Value Per Share 464.16 9.75 10.18 8.87 8.79

Fiscal Year End for Hikma Pharmaceuticals Plc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,794 -99,999 -99,727 -99,999
Receivables NA 873 NA 905 NA
Notes Receivable NA NA NA NA NA
Inventories NA 891 NA 859 NA
Other Current Assets NA 131 NA 140 NA
Total Current Assets NA 2,100 NA 2,176 NA
Net Property & Equipment NA 1,096 NA 1,032 NA
Investments & Advances NA 113 NA 72 NA
Other Non-Current Assets NA NA NA NA NA
Deferred Charges NA 226 NA 200 NA
Intangibles NA 1,100 NA 1,084 NA
Deposits & Other Assets NA NA NA NA NA
Total Assets NA 4,680 NA 4,619 NA
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA NA NA
Accounts Payable NA 568 NA 505 NA
Current Portion Long-Term Debt NA 150 NA 211 NA
Current Portion Capital Leases NA 11 NA 10 NA
Accrued Expenses NA NA NA NA NA
Income Taxes Payable NA 74 NA 73 NA
Other Current Liabilities NA 536 NA 416 NA
Total Current Liabilities NA 1,339 NA 1,215 NA
Mortgages NA NA NA NA NA
Deferred Taxes/Income NA 25 NA 26 NA
Convertible Debt NA NA NA NA NA
Long-Term Debt NA 975 NA 1,032 NA
Non-Current Capital Leases NA 55 NA 59 NA
Other Non-Current Liabilities NA NA 85 NA
Minority Interest (Liabilities) NA NA NA NA NA
Total Liabilities NA 2,471 NA 2,417 NA
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA NA NA
Common Stock (Par) NA 40 NA 40 NA
Capital Surplus NA 282 NA 282 NA
Retained Earnings NA 2,158 NA 2,146 NA
Other Equity NA -271 NA -266 NA
Treasury Stock NA NA NA NA NA
Total Shareholder's Equity NA 2,209 NA 2,202 NA
Total Liabilities & Shareholder's Equity NA 4,680 NA 4,619 NA
Total Common Equity 0 102,208 0 102,201 0
Shares Outstanding 220.20 220.20 220.20 220.20 220.20
Book Value Per Share 0.00 464.16 0.00 464.13 0.00